Copied from Dow Jones News Wires.........
By Josh Beckerman
VolitionRx shares rose 35% Tuesday after the company said it received $13 million in milestone payments from Heska in connection with a March 2022 licensing agreement.
Epigenetics company VolitionRx said in a securities filing that the payments arose from the successful assay transfer of its Nu.Q Vet Cancer Test onto Heska's Element i+ Immunodiagnostic Analyzer veterinary diagnostics platform. Mars bought Heska in June.
To keep, the few of us who might be watching this site for news, updated.